A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
17 September, 2026
Meet the TROG Quality Assurance team
TROG UPDATES: 17 September 2026 Our Quality Assurance team
17 September, 2026
TROG trial of new lung cancer radiation therapy approach opens
LATEST NEWS: 17 September 2026 The first Australian site